ProCE Banner Activity

Can a Long-Acting ART Regimen Be an Option for Patients With HIV/HBV Coinfection?

Clinical Thought
Long-acting regimens do not contain HBV active agents, and therefore, it is vital to assess an individuals hepatitis B status before switching.

Released: January 25, 2022

Expiration: January 24, 2023

Share

Faculty

Gail Matthews

Gail Matthews, MD, PhD, Prof

Program Head, Kirby Institute
University New South Wales
Specialist, Department of Infectious Diseases
St Vincent's Hospital
Sydney, Australia

Supporters

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Gail Matthews, MD, PhD, Prof

Program Head, Kirby Institute
University New South Wales
Specialist, Department of Infectious Diseases
St Vincent's Hospital
Sydney, Australia

Prof Gail Matthews, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca and Janssen and funds for research support from AbbVie, Gilead Sciences, and ViiV.